CN
Home
Home
About Us
About Us
Ark Overview
Our Team
Our History
Our Culture
Our Advisors
Research
Research
Pipeline
Pipeline
Media
Media
Ark News
Career
Career
Contact Us
Contact Us
Investor relations
Investor relations
Corporate Governance
Board Members
Announcements and Circulars
Stock Information
IR
Home
About Us
Ark Overview
Our Team
Our History
Our Culture
Our Advisors
Research
Pipeline
Media
Ark News
Career
Contact Us
Investor relations
Corporate Governance
Board Members
Announcements and Circulars
Stock Information
IR
Ark News
2023
2022
2021
2020
2019
2018
2022-12-09
Ark Biopharmaceutical Announces NMPA Acceptance and Priority Review of New Drug Application for Ziresovir for Treatment of RSV Infection
China’s National Medical Products Administration (NMPA) has formally accepted and granted Priority Review of its New Drug Application (NDA) for ziresovir (AK0529) for treatment of respiratory syncytial virus (RSV) infection.
2022-10-07
Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-Infected Hospitalized Infants at 12th International RSV Symposium
The study met both the primary endpoint of reduction in signs-and-symptoms (S&S) score on day 3 of treatment, and the key secondary endpoint of reduction in viral load on day 5, compared with placebo
2022-04-07
Ark Biopharmaceutical Announces Positive Results of Phase 3 Study with Ziresovir in Infants and Children Hospitalized with Respiratory Syncytial Virus Infection
The first antiviral drug successfully completing a pivotal phase 3 study in this patient population
2022-01-25
Ark Biopharmaceutical Announces Completion of Patient Enrollment and Dosing in AIRFLO, a Phase III Registration Trial of Ziresovir for Treatment of Respiratory Syncytial Virus Infection
This is the first time ever that a phase III clinical trial of an RSV-specific therapeutic has been completed. Topline results are expected to be available in the first half of 2022.
Prev
1
Next
TOP
Home
Tel
Top
TOP
Telephone：
Address：
E-mail：
CN
